related to what information must be included within a handset model's packaging either in the form of a printed insert or a printed handset manual. The Commission is requiring that a handset model's external printed package label indicate whether the handset model includes Bluetooth coupling capabilities or telecoil coupling capabilities or both, and in the case of Bluetooth coupling which Bluetooth technology the handset model incorporates. The Commission is also requiring handset manufacturers and service providers to include information on the hearing aid compatibility settings of handset models and how consumers can turn these settings on and off. As part of these revisions, the Commission eliminated outdated labeling requirements which were no longer necessary and that might cause consumer confusion if retained. By eliminating these outdated requirements, the Commission reduced regulatory burden and cost to handset manufacturers and service providers. The revised labeling requirements are in section 20.19(f)(1) and (2) of the Commission's rules and these revised requirements ensure that consumers have the information that they need to make informed handset model purchasing decisions.

In addition to these revised labeling rules, the Commission determined to allow handset manufacturers and service providers to use digital labeling technology as an alternative to including a printed insert or printed handset manual in a handset model's packaging. Handset manufacturers and service providers choosing this option must maintain publicly accessible websites where consumers can find the required hearing aid compatibility information, and they must provide consumers with a Quick-Response (QR) code and the related website address where the required hearing aid compatibility information can be found. The Commission decided to allow the use of digital labeling technology at the request of handset manufacturers and service providers who argued that the use of digital labeling would reduce regulatory burden and cost for them. The use of digital labeling will also ensure that consumers have access to the most up-to-date handset model information. The Commission's new digital labeling rules are at section 20.19(f)(3) of the Commission's rules.

Along these same lines, the Commission revised its website posting requirements that apply to handset manufacturers and service providers who maintain publicly accessible websites. These companies must indicate on their publicly accessible websites which handset models that they offer for sale or use in the United States meet telecoil certification requirements and which meet Bluetooth coupling requirements. In addition, these companies must list a handset model's conversational gain if the handset model was certified as hearing aid-compatible using a standard that includes volume control requirements. The Commission also adopted point-of-contact requirements that require handset manufacturers and service providers to list contact information that consumers can use to ask knowledgeable company employees compatibility questions that they might have concerning the handset models that these companies offer for sale or use in the United States. Part of these revisions also included eliminating out-of-date website posting and record retention requirements that no longer served a useful purpose. The elimination of these outdated information collection requirements reduce regulatory burden and cost for handset manufacturers and service providers. The revised website posting requirements are at section 20.19(h) of the Commission's rules.

Finally, the Commission revised its annual certification requirements for handset manufacturers and service providers. After the 100% hearing aid compatibility transition period ends for handset manufacturers, these companies will no longer file FCC Form 655. Instead, handset manufacturers will start filing FCC Form 855 and service providers will continue to file this form. FCC Form 855 is a streamlined certification form that does not require the detail handset model information that FCC Form 655 collects. This change will significantly reduce regulatory burden and cost for handset manufacturers. In addition, the Commission is updating FCC Form 855 to ensure it collects only relevant information consistent with the Commission's 100% hearing aid compatibility requirement. These updates include removing outdated questions and streamlining the information that the form collects. The revised annual certification requirements are at section 20.19 (i)(4) and (5) of the Commission's rules.

Federal Communications Commission.

Marlene Dortch,

Secretary, Office of the Secretary.

[FR Doc. 2025–04645 Filed 3–18–25; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL MARITIME COMMISSION

Notice of Agreements Filed

The Commission hereby gives notice of the filing of the following agreement under the Shipping Act of 1984. Interested parties may submit comments, relevant information, or documents regarding the agreement to the Secretary by email at *Secretary@fmc.gov,* or by mail, Federal Maritime Commission, 800 North Capitol Street Washington, DC 20573. Comments will be most helpful to the Commission if received within 12 days of the date this notice appears in the **Federal Register**, and the Commission requests that comments be submitted within 7 days on agreements that request expedited review. Copies of the agreement are available through the Commission's website (*www.fmc.gov*) or by contacting the Office of Agreements at (202)–523–5793 or *tradeanalysis@fmc.gov.*

Agreement No.: 011931–012.

Agreement Name: CMA CGM/Marfret Vessel Sharing Agreement for PAD Service.

Parties: CMA CGM S.A.; Maritime Marfret S.A.S.

Filing Party: Draughn Arbona; CMA CGM (America) LLC.

Synopsis: The Amendment expands the agreement's geographic scope to include Colombia and revises the agreed reefer slot allocation.

Proposed Effective Date: 4/21/2025.

Location: https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/512.

Dated: March 14, 2025.

Alanna Beck,

Federal Register Alternate Liaison Officer.

[FR Doc. 2025–04561 Filed 3–18–25; 8:45 am]

BILLING CODE 6730–02–P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at

the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at *https://www.federalreserve.gov/foia/request.htm.* Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than April 3, 2025.

A. Federal Reserve Bank of New York (Bank Applications Officer) 33 Liberty Street, New York, New York 10045–0001. Comments can also be sent electronically to *Comments.applications@ny.frb.org:*

1. *Dahlia D'Angelo, Sarasota, Florida; George Fred D'Angelo, Jr., Jake D'Angelo, Derek D'Angelo and Kerry Elizabeth D'Angelo, all of Old Greenwich, Connecticut;* to become members of the D'Angelo Family Group, a group acting in concert, to retain voting shares of First Greenwich Financial, Inc. (FGFI), and thereby indirectly retain voting shares of First Bank of Greenwich, both of Cos Cob, Connecticut.

In addition, *The D'Angelo Family Trust, Naples, Florida, Dahlia D'Angelo and George Fred D'Angelo, Jr., as co-trustees;* to join the D'Angelo Family Group, to acquire voting shares of FGFI, and thereby indirectly acquire voting shares of First Bank of Greenwich.

B. Federal Reserve Bank of Kansas City (Jeffrey Imgarten, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001. Comments can also be sent electronically to *KCApplicationComments@kc.frb.org:*

1. *The Kincaid Trust dated January 16, 2024, Jeff Kincaid and Pamela Kincaid, as co-trustees, all of Lenexa, Kansas;* to join the Kincaid Family Group, a group acting in concert, to acquire voting shares of Northeast Kansas Bancshares, Inc., and thereby indirectly acquire voting shares of Kendall Bank, both of Overland Park, Kansas; as well as, Orrick Financial Corporation and TBO Bank, both of Orrick, Missouri.

Board of Governors of the Federal Reserve System.

Erin Cayce,

Assistant Secretary of the Board.

[FR Doc. 2025–04587 Filed 3–18–25; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: Findings of research misconduct have been made against Liping Zhang, Ph.D. (Respondent), former Assistant Professor in the Department of Medicine, Section of Nephrology, Baylor College of Medicine. Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), grants R37 DK037175 and P30 DK079638 and National Cancer Institute (NCI), NIH, grant P30 CA016672. Administrative actions, including debarment for a period of two (2) years, were implemented and are detailed below.

FOR FURTHER INFORMATION CONTACT: Sheila R. Garrity, JD, MPH, MBA, Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453–8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) and the Suspension and Debarment Official (SDO) have taken final action in the following case:

Liping Zhang, Ph.D., Baylor College of Medicine (BCM): Based on evidence from an investigation conducted by BCM, ORI's oversight review of BCM's investigation, and additional evidence obtained and analysis conducted by ORI during its oversight review, ORI found that Dr. Liping Zhang, former Assistant Professor in the Department of Medicine, Section of Nephrology, BCM, engaged in research misconduct under 42 CFR part 93 in research supported by PHS funds, specifically NIDDK, NIH, grants R37 DK037175 and P30 DK079638 and NCI, NIH, grant P30 CA016672.

ORI found by a preponderance of the evidence that Respondent intentionally and knowingly falsified and/or fabricated western blot images and microscopy images by manipulating the images, using unrelated images, or reusing and relabeling the same images to represent falsely different experimental results in three (3) PHS-supported unpublished manuscripts submitted for publication and four (4) grant applications submitted for PHS funds. ORI found that these acts constitute a significant departure from accepted practices of the relevant research community.

The affected manuscripts and grant applications are:

- Nucleolar protein 66 functions as a novel negative regulator of satellite cells. Original manuscript submitted to *EMBO Reports* in October 2017 (hereafter referred to as ''*EMBO Rep.* First Submission'').
- Nucleolar protein 66 functions as a novel negative regulator of satellite cells. Second submission to *EMBO Reports* in April 2018 (hereafter referred to as ''*EMBO Rep.* Second Submission'').
- NO66, an endogenous mediator of muscle growth, suppresses myogenic genes by forming repressive complex with RBBP4 and HDAC2. Original manuscript submitted to *Cell Reports* in July 2015 (hereafter referred to as ''*Cell Rep.* Submission'').
- R01 DK037175–32, ''Protein nutrition in experimental uremia,'' submitted to NIDDK, NIH, on March 3, 2017, awarded from May 2, 2018–March 31, 2022.
- R01 AR070845–01A1, ''A new pathway to muscle atrophy in chronic kidney disease,'' submitted to National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, on November 3, 2016, administratively withdrawn by NIAMS on March 1, 2019.
- R01 AR069533–01A1, ''Epigenetic control of skeletal muscle development and aging-related muscle regeneration,'' submitted to NIAMS, NIH, on March 1, 2016, administratively withdrawn by NIAMS on November 1, 2018.
- R01 DK116886–01, ''A demethylase-dependent mechanism regulates whitening of brown adipocytes and obesity,'' submitted to NIDDK, NIH, on June 2, 2017, administratively withdrawn by NIAMS on November 2, 2019.

Specifically, ORI found by a preponderance of the evidence that Respondent engaged in research misconduct by intentionally and knowingly falsifying and/or fabricating: